The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Clonal evolution in MPNs: molecular monitoring and implications for treatment
Paola Guglielmelli, MD, PhD, Careggi University Hospital, Florence, Italy, discusses clonal evolution in myeloproliferative neoplasms (MPNs), exploring when molecular monitoring should be performed and how findings can guide treatment decisions. Dr Guglielmelli highlights the prognostic significance of driver mutations, variant allele frequency (VAF), and high-risk mutations, emphasizing the need for standardized approaches to molecular monitoring and treatment adaptation. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
